SMAD2 and ovarian cancer: We knocked down AP3S1 in ovarian cancer cells and observed a decrease in the protein levels of TGF-β, phosphorylated SMAD2/3 (p-SMAD2/3), vimentin (VIM), and N-cadherin, whereas E-cadherin levels were increased (Fig. 10A).